From ultrasound therapies to brain-computer interfaces, this week’s MedTech funding activity highlights investor confidence in technologies reshaping diagnostics, intervention, and patient care. Details follow below.
Cagent Vascular closes $41M Series D
The company plans to use proceeds to fund a global pivotal trial and the eventual commercial launch of Sonic IVL. It also plans to use funds to support future applications of the IVL platform in coronary arteries.
U.S. Venture Partners (USVP) and Astoria Health Investors provided funding for the $41M funding round.
CEO Brian Walsh
Last week’s tracker: NVision, BlueWind & more
Sound Wave Innovation raised $17M for ultrasound Alzheimer’s therapy
The Series C round will support the completion of the company’s pivotal clinical trial, which is expected to conclude by the end of 2026, according to The Wall Street Journal.
The financing round was led by iGlobe Partners and included participation from existing investors such as Sumitomo Heavy Industries and Fiducia, alongside other domestic and international venture capital firms, medical companies, and individual investors.
Founder and CEO Hiroaki Shimokawa
Vortex Imaging secures $12M for 3D imaging expansion
The funding round attracted a robust syndicate of both new and returning institutional investors. Participants included 10D Ventures, Entrée Capital, Harel T.E.C. Partnership, Connecticut Innovations, and PhiFund Ventures.
Funds will be used to speed clinical development, approval and commercial launch of its cloud-enabled computational ultrasound platform.
CEO Tomer Ben David
QT Imaging closes $10M stock and pre-funded warrant offering
QT Imaging Holdings completed an underwritten public offering of 1,200,000 common shares and 800,000 pre-funded warrants for gross proceeds of $10 million, generating estimated net proceeds of about $9 million.
The common shares were priced at $5.00 per share and the pre-funded warrants at $4.9999 each, with a nominal exercise price of $0.0001 per warrant share.
CEO Raluca Dinu
Neurosoft Bioelectronics closes $7.5M seed funding round to support BCI
The round, led by Skybound Venture Capital, brings the company’s total funding to more than $20M to date. PL Capital, IAG Capital Partners and Connecticut Innovations, among others, also participated.
With the funding, the company plans to advance its near-term milestones, including demonstrating minimally invasive deployment in human patients and achieving U.S. commercialization of its first BCI.
CEO Nicolas Vachicouras
Efferon raises $2.9M in Seed funding
Efferon, a Villach, Austria-based biotech company manufacturing multimodal hemoadsorption therapeutic devices, raised $2.9M in Seed funding. Backers were not disclosed.
The company intends to use the funds to accelerate the expansion of its U.S. office and strengthen the local team.
CEO Dima Romashin
NEX Health Intelligence secures €1M Pre-Seed round
The company will use the funds to predict where drug-resistant infections will spread next inside hospitals.
The round was led by Brighteye Ventures, with participation from Adeline Arts and Science, AFI Ventures (Ventech), MOMENTOUS., the Conception X Angel Syndicate, and industry angels.
Founder and CEO Ashleigh Myall
Instalimb secures funding from Orthomos Investment
The company has conducted a funding round through J-KISS type stock acquisition rights with Orthomos Investment, the investment arm of the Orthomos Group, as the underwriter.
Additionally, the company has signed a basic agreement with Alcare of the same group in the field of prosthetics and orthotics.
CEO Yutaka Tokushima
VCD Medical completes fourth funding round and implements stock option plan
Partner Andrea Vaglié and counsel Ferdinando Pasello managed the tax profiles of the transaction, while partner Francesco Lamperti and senior associate Michela Santinelli oversaw the legal aspects.
Pirola Pennuto Zei & Associati assisted VCD Medical throughout the process with a multidisciplinary team.
CEO Francesco Piccagli
Chinese brain-computer interface developer Qiannao Tech raises Seed+ round
The funding will support clinical trials, medical device registration, core technology iteration and market expansion, accelerating the commercialisation of the company’s brain health monitoring products.
The round was co-led by prominent entrepreneurs and investors, with participation from existing shareholders.
Founder Han Bicheng
